|
|
 |
|
Viewing report
|
|
|
|
Hepatitis C Therapeutics Market—Thailand
Frost & Sullivan, Dec 2009, Pages: 58
This research service aims to provide an update on the epidemiology of Hepatitis C, including the prevalence and incidence, market engineering measurements, and government initiatives. It also covers patient source, load, and forecasts, while also outlining the key treaters involved. Current diagnostic methods are presented, followed by treatment regimens, their cost, and upcoming product launches. Clinical trials highlighting research into new treatments are also provided, along with an analysis of the pipeline. Additionally, there is a competitive analysis which includes the market structure, major participants, and future trends. This service covers the Hepatitis C therapeutics market in Thailand.
Research Overview
This Frost & Sullivan research service titled Hepatitis C Therapeutics Market—Thailand provides an in-depth analysis of the market drivers and restraints, industry trends, and competitive environment in addition to the challenges and issues faced by market participants. The study also examines government initiatives, patient load, classification, treatment regimens, and product launches.
This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
Market Overview
Increased Screening Procedures Widen Patient Base and Boost Outlook for the Hepatitis C Therapeutics Market in Thailand
With the stepping up of screening efforts, the diagnosed patient pool has been continuously expanding and uplifting prospects for the hepatitis C therapeutics market in Thailand. However, only 2.6 percent of those diagnosed resort to treatment because of the high costs involved and the lack of government reimbursement. Thailand achieved universal healthcare coverage in 2002, and the entire population is covered by three main public health financing schemes. The Social Security Scheme (SSS) covers the employees of the formal sector, while the Civil Servants' Medical Benefit Scheme (CSMBS) covers government employees and their dependents. The rest of the population is covered by the Universal Healthcare Coverage (UC) Scheme, which is the most recent initiative. In terms of hepatitis C, only patients who are civil servants are entitled to full reimbursement under the CSMBS. Those who are not entitled need to bear the treatment expenses themselves.
The prevailing hepatitis C virus (HCV) treatment options often engender non compliance largely due to persistent side effects, limited efficacy for those infected with genotype 1 strain, and dosing frequency. The current treatment regimen of Pegylated Interferon and Ribavirin for hepatitis C have strong side effects, such as lowered blood platelet count, depression, and hemolytic anemia besides having lowered efficacy for the genotype 1 strain. According to physicians, those afflicted with hepatitis C genotype 1 have a sustained viral response of 50 percent to current therapy. With 40 percent of those diagnosed with hepatitis C in Thailand having the genotype 1 strain, the current drug offerings are unable to capture a sizeable portion of the market. In such a scenario, opportunities are unfolding for new treatment options. Refined versions of interferons, oral formulations of small molecule inhibitors, and the new drug class known as protease inhibitors are in the pipeline and represent the future of HCV treatment.
Encouraging better compliance now will increase the likelihood of future compliance, especially for improved treatments. Creating incentives for patients to stay on HCV treatment will increase the chances of patient compliance. Unleashing marketing campaigns that highlight better efficacy, establishing partnerships with governments to decrease costs and increase distribution, and broadening the scope of diagnosis will boost market presence. Initiatives by pharmaceutical companies such as Bristol-Myers Squibb have helped patients to know more about the disease, the treatment options available, and the importance of getting timely treatment. Although urban awareness programs have widened the treatment base, they fail to reach the 60 percent of the population that live in rural areas. This represents missed treatment opportunities and thus, market share. In order to increase their HCV market share with newer drugs, pharmaceutical companies must make sure that patients are aware of their disease status and willing to take them. Realizing the need for shortened therapy, companies are undertaking studies to investigate reduction in treatment length for HCV genotypes 2 and 3 to 16 weeks, 14 weeks, or even 12 weeks. Several companies with pipeline interferon therapies are addressing these issues by developing long-acting interferons that have reduced frequency of dosing and a lower incidence of side effects.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Singapore
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in Hong Kong
Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in South Korea
Multi Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in China
Multi-client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in Malaysia
Hepatitis C Therapeutics Market – Taiwan
Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in India
Multi-Client Study: Opportunities Assessment for the Hepatitis C Therapeutics Market in the Philippines
R&D Trends: Hepatitis C
Hepatitis C Virus and Therapeutics - Global Strategic Business Report
|
|
|
|
